Dr. Hua Xiao 肖华
Chief Physician
Department of Hepatobiliary and Intestinal Surgery, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of gastric cancer, colorectal cancer, liver cancer, bile duct cancer, and gastrointestinal stromal tumors. Focuses on perioperative management and prevention of postoperative complications for these conditions.
Dr. Xiao holds a clinical medicine doctorate from Tongji Medical College, Huazhong University of Science and Technology, studying under Academician Chen Xiaoping of the Chinese Academy of Sciences. Dr. Xiao has led seven projects, including Hunan Provincial Natural Science Foundation grants, and participated in multiple National Natural Science Foundation projects. Dr. Xiao has published over 30 papers as first or corresponding author in journals such as Ann Surg Oncol and Chinese Medical Journal.
Professional roles
- Member, International Gastric Cancer Association
- Youth Committee Member, Pancreatic Disease Society, China International Exchange and Promotion Association for Medical and Health Care
- Youth Committee Member, Liver Cancer Professional Committee, China Anti-Cancer Association
- Committee Member, Intestinal Obstruction Branch, Hunan Geriatric Medical Association
Name order: in Chinese the family name comes first (Xiao Hua). Papers usually list the name as Hua Xiao or Xiao H.
Selected publications
45 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (first author): Silencing of circRERE(4-5) inhibits ONECUT2-mediated tumorigenesis and metastasis in gastric cancer. PubMed 41869354
- Front Oncol, 2026 (senior author): Validation of the predictive value of combined prealbumin and lymphocyte score for prognosis of stage II/III gastric cancer following curative resection. PubMed 41768246
- J Inflamm Res, 2025 (first author): Comment on "Peripheral T Lymphocyte Predicts the Prognosis of Gastric Cancer Patients Undergoing Radical Gastrectomy: A Multicenter Retrospective Cohort Study" [Response to Letter]. PubMed 40255657
- BMC Gastroenterol, 2024 (first author): Prognostic factors and adjuvant chemotherapy efficacy in stage I gastric cancer patients: a retrospective analysis. PubMed 39719607
- J Inflamm Res, 2024 (first author): Peripheral T Lymphocyte Predicts the Prognosis of Gastric Cancer Patients Undergoing Radical Gastrectomy: A Multicenter Retrospective Cohort Study. PubMed 39670156
- Gastric Cancer, 2023 (first author): Prognostic value of post-operative serum procalcitonin in gastric adenocarcinoma patients undergoing radical gastrectomy: propensity score matching analysis of extended cohort from a prospective bi-center study. PubMed 37578602
- Eur J Clin Nutr, 2022 (senior author): Association among prognostic nutritional index, post-operative infection and prognosis of stage II/III gastric cancer patients following radical gastrectomy. PubMed 35354923
- Front Oncol, 2022 (senior author): Body Mass Index and Prognosis of Patients With Stage II/III Gastric Cancer After Curative Gastrectomy: Completion of Perioperative Adjuvant Chemotherapy May Be a Confounding Factor. PubMed 35769709
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion